Pharma, Policy

Bail be damned: Martin Shkreli gets OK to go to Washington

Martin Shkreli won't violate the terms of his bail when he travels to Washington to appear before a congressional committee on drug pricing, the U.S. DOJ writes.

Martin Shkreli

Looks like it’s OK for our drug price gouging buddy Martin Shkreli to head to Washington this and testify before that drug pricing congressional committee, Stat News reports.

The U.S. Department of Justice yesterday wrote a letter that  sanctions Shkreli’s travel to D.C. for a Feb. 4 hearing – despite Shkreli saying he couldn’t leave New York thanks to the terms of his bail.

Shkreli, after all, is out on a $5 million bail for unrelated securities fraud charges for his “Ponzi-like” scheming at previous companies. The former Turing Pharmaceuticals CEO is entwined in a complex web of legal issues – with an FTC investigation underway for antitrust violations, a congressional subpoena for drug price gouging and, of course, securities fraud.

The hearing was initially scheduled for Jan. 26, but postponed to February due to the recent blizzard.

Shares0
Shares0